About Us

Company Profile

Gamida Cell is a leader in the development of cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. Our world-class scientists are harnessing epigenetic science to develop a broad platform technology that provides a safe and effective way to expand functional cells in culture to create curative treatments for patients.

Our lead clinical program, NiCord®, has received U.S. Breakthrough Therapy Designation and is currently in phase 3 clinical testing as a universal bone marrow transplant solution for patients unable to find a suitable matched donor. In pilot and phase 1/2 studies, NiCord achieved the first evidence of an ex vivo expanded graft providing a rapid and robust hematopoietic recovery following infusion.

Write to Us